Related references
Note: Only part of the references are listed.Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program
Rachel M. Wake et al.
CLINICAL INFECTIOUS DISEASES (2020)
Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management
Katelyn A. Pastick et al.
MEDICAL MYCOLOGY (2020)
Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial
Joseph N. Jarvis et al.
CLINICAL INFECTIOUS DISEASES (2019)
Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/μL: A Stepped-Wedge, Cluster-Randomized Trial
David B. Meya et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2019)
Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries
Angela Loyse et al.
LANCET INFECTIOUS DISEASES (2019)
Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis
Radha Rajasingham et al.
PLOS ONE (2019)
A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda
Elizabeth Nalintya et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2018)
Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa
S. F. Molloy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Radha Rajasingham et al.
LANCET INFECTIOUS DISEASES (2017)
Estimating the cost-per-result of a national reflexed Cryptococcal antigenaemia screening program: Forecasting the impact of potential HIV guideline changes and treatment goals
Naseem Cassim et al.
PLOS ONE (2017)
Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program
Tafese Beyene et al.
CLINICAL INFECTIOUS DISEASES (2017)
County-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research
Beth Woods et al.
VALUE IN HEALTH (2016)
Single-Dose Indigenous Liposomal Amphotericin B in the Treatment of Indian Visceral Leishmaniasis. A Phase 2 Study
Shyam Sundar et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2015)
Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial
Sayoki Mfinanga et al.
LANCET (2015)
Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality
Emilio Letang et al.
OPEN FORUM INFECTIOUS DISEASES (2015)
Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes
Joseph N. Jarvis et al.
CLINICAL INFECTIOUS DISEASES (2014)
Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries
Dorita Avila et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study
Renee Donahue Carlson et al.
METABOLIC BRAIN DISEASE (2014)
Multisite Validation of Cryptococcal Antigen Lateral Flow Assay and Quantification by Laser Thermal Contrast
David R. Boulware et al.
EMERGING INFECTIOUS DISEASES (2014)
Rates and Cost of Hospitalization Before and After Initiation of Antiretroviral Therapy in Urban and Rural Settings in South Africa
Gesine Meyer-Rath et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries
Angela Loyse et al.
LANCET INFECTIOUS DISEASES (2013)
Long Term 5-Year Survival of Persons with Cryptococcal Meningitis or Asymptomatic Subclinical Antigenemia in Uganda
Elissa K. Butler et al.
PLOS ONE (2012)
Cryptococcal Meningitis Treatment Strategies in Resource-Limited Settings: A Cost-Effectiveness Analysis
Radha Rajasingham et al.
PLOS MEDICINE (2012)
Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ≤100 Cells/mL Who Start HIV Therapy in Resource-Limited Settings
David B. Meya et al.
CLINICAL INFECTIOUS DISEASES (2010)
Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South Africa
Joseph N. Jarvis et al.
CLINICAL INFECTIOUS DISEASES (2009)
Share Paper
